Monday, November 17, 2014 9:12:52 AM
8:40a ET November 17, 2014 (Benzinga)
Analysts at Canaccord Genuity initiated coverage on shares of Mast Therapeutics (NYSE: MSTX) with a Buy rating.
The target price for Mast Therapeutics is set to $3.
Mast Therapeutics' shares jumped 11.11% to $0.50 in pre-market trading.
Latest Ratings for MSTX DateFirmActionFromTo
Nov 2014Canaccord GenuityInitiates Coverage onBuy Oct 2013Canaccord GenuityInitiates Coverage onBuy
View More Analyst Ratings for MSTX
View the Latest Analyst Ratings
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM